Katy Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology shared on X:
“ENZAMET at 8 years shows the early benefit persists vs nonsteroidal antiandrogen
- Median OS 7.9 vs 5.8 yr, HR 0.73
- 8-yr clinical PFS 43% vs 20%
- Deaths from other causes 78 vs 76, no excess
- Falls were more frequent (0.70 vs 0.24 per 100 person-yr).
Why this matters for your practice: the comparator is a first-generation NSAA, so this does not re-rank first-line choices.
It does give the maturest long-term safety read on an ARPI in mHSPC. Congrats to Christopher Sweene and huge team, recognition for this longterm effort.”
Katy Beckermann was recognized among OncoDaily’s The 100 Most Influential People in Oncology in 2025, highlighting her contributions to the field of oncology.
Nominations for 100 Influential People in Oncology 2026 are now open, recognizing leaders, researchers, clinicians, innovators, advocates, and other individuals making a meaningful impact on oncology and cancer care.
Don’t miss the opportunity to nominate yourself, a colleague, or someone whose contributions deserve to be recognized.
Submit your nomination by September 15: 100 Influential People in Oncology 2026 – Nominations are Open!
You can also read: 2026 Advances in Prostate Cancer Management: A Multidisciplinary Approach
